Loading...

ANNX ANNEXON INC Operational Disruptions 8-K Filing

NNXN

NNX

ANNEXON INC

(ANNX)

2024 8-K

Show Summary

Summary

Financial Results

Common Warrant Amendments

Financial Statements

Financial Results

2025 Outlook Announcement

Director Appointment

Positive Study Results

Q3 2024 Results

Q2 2024 Results

Update on ARCHER II Global ...

Positive Phase 3 Results fo...

Annual Meeting Voting Results

Underwriting Agreement

Phase 3 Trial Results

Financial Results Announcement

Financial Results

R&D Day Presentation

Filing Correction and Under...

Entry into a Material Defin...

Global Registrational Progr...

Financial Results

Financial Results

Appointment, Trial Results

Annual Meeting Voting Results

Results Announcement

Financial Results

Financial Results Announcement

Investor Conferences

Appointment of Chief Scient...

External Links:

Annexon, Inc. announced positive results from a Phase 3 clinical trial for their C1q blocking antibody ANX005 in Guillain-Barre syndrome, meeting its primary endpoint and demonstrating improvements on secondary endpoints.

AI Assistant

ANNEXON INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.